The purpose of this study is to evaluate the visual performance of a new multifocal High ADD contact lens compared to the currently-marketed AIR OPTIX® AQUA MULTIFOCAL (AOAMF) High ADD Contact Lens.

Inclusion Criteria:

• Must sign an Informed Consent document;
• Presbyopic and require at least 2.25 diopters (D) spectacle ADD power;
• Current or previous soft contact lens wearer;
• Not able to achieve monocular near visual acuity (VA) 0.2 logarithm of the Minimum Angle of Resolution (logMAR) [Early Treatment of Diabetic Retinopathy Study (ETDRS)] or better in each eye with AIR OPTIX® AQUA Multifocal (AOAMF) High ADD Contact Lenses;
• Willing and able to wear multifocal contact lenses in both eyes within the available range of powers for this trial;
• Manifest cylinder less than or equal to 1.00 D;
• Able to achieve best corrected visual acuity (BCVA) of 20/25 or better in each eye at distance (as determined by manifest refraction);
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment, as determined by the investigator;
• Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; or any use of topical ocular medications that would require instillation during contact lens wear;
• Any history of herpetic keratitis;
• History of corneal or refractive surgery, irregular cornea or unilateral pseudophakia;
• Biomicroscopy findings (except for corneal vascularization) that are moderate (Grade 3) or severe (Grade 4);
• Corneal vascularization that is mild (Grade 2) or higher;
• A pathologically dry eye that precludes contact lens wear;
• Monocular (only 1 eye with functional vision);
• Anisometropia ≥ 1.50 D (contact lens distance prescription);
• Clinically significant (> 1 millimeter) anisocoria;
• History of intolerance or hypersensitivity to any component of the investigational products;
• Concurrent participation in a contact lens or contact lens care product clinical trial within the previous 30 days;
• Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment;
• Any ocular or systemic medical condition that may, in the opinion of the Investigator, preclude safe administration of the study lenses or affect the results of this study;
• Other protocol-defined exclusion criteria may apply.

This analysis population includes all randomized and treated subjects.

Adverse events (AEs) were collected for the duration of the study (3 months). AEs are reported as pre-treatment and treatment-emergent, based on treatment-specific exposure.

An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users, or other persons, whether or not related to the investigational medical device. AEs were obtained as solicited comments from subjects and as observations by the study Investigator as outlined in the study protocol.